August 11, 2026

Can Daylight Saving Time Affect Retinal Vascular Disease?

Investigators examined whether daylight saving time transitions were associated with newly diagnosed retinal vascular disease.

MDSpire News

August 03, 2026

Enzyme Disruption Could Impair Retinal Homeostasis

Preclinical models showed that impaired endolysosomal trafficking preceded photoreceptor degeneration and disrupted retinal pigment epithelial cell function.

MDSpire News

July 24, 2026

0.3% HA Eye Drops May Improve Dry Eye

A prospective multicenter study found improvements in ocular surface integrity, tear-film stability, tear production, and symptom burden over 60 days in patients with moderate-to-severe dry eye disease.

MDSpire News

July 20, 2026

Can Patients Switch to Biosimilar Aflibercept?

A 20-week INSIGHT extension suggests that switching from reference aflibercept to MYL-1701P maintained comparable safety, visual, and anatomic outcomes in patients with diabetic macular edema.

MDSpire News

July 20, 2026

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

MDSpire News

July 14, 2026

Are GLP-1s Linked to Optic Neuropathy?

A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.

MDSpire News

July 13, 2026

Side Effects: Signals in Strange Places

From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.

MDSpire News

July 13, 2026

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

MDSpire News

July 08, 2026

DIMS Wear Linked to Slower Axial Growth

Nearly 10 years of observational follow-up suggested sustained axial-length slowing, although refractive findings were less consistent and comparisons relied on statistical modeling.

MDSpire News

July 08, 2026

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

MDSpire News